Renin-angiotensin-system-acting agents for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 hospitalized meta-analysis
Nouri-Vaskeh IRCT20180802040678N4		RCT	angiotensin receptor blockers (ARBs)	calcium channel blocker	COVID 19 hospitalized	some concern	41/41	inconclusive	inconclusive 65 % decrease in deaths (PE) with a moderate degree of certainty due to some concern in risk of bias
COVID-19 mild to moderate meta-analysis
Lopes (BRACE CORONA) NCT04364893		RCT	discontinuation of ACEI/ARB	continuation of ACEI/ARB	COVID-19 mild to moderate	some concern	371/369	inconclusive
9 studies excluded by filtering options (2 RCT / 7 OBS)

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 hospitalized meta-analysis

COVID-19 mild to moderate meta-analysis